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and S108N in the pfdhfr Gene Are Independently Associated with
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Screening for in vitro susceptibility to pyrimethamine and sequencing of the pfmdr2 and pfdhfr genes were performed in 140
Plasmodium falciparum isolates. The risk of in vitro resistance to pyrimethamine was analyzed with a logistic regression model.
The mutation F423Y in pfmdr2 (odds ratio [OR] 2.12 [confidence interval {CI}, 1.02 to 4.59]; P 0.0489) and the mutation
N51I, C59R, or S108N in pfdhfr (OR 42.34 [CI, 5.52 to 324.61]; P 0.0003) were independently associated with in vitro resis-
tance to pyrimethamine.
Sulfadoxine and pyrimethamine (Pyr) (SP) were widely used asfirst-line drugs for the treatment of malaria until the spread of
resistance in Plasmodium falciparum isolates all over the world. SP
is still recommended in combination with artesunate or chloro-
quine as a second-line therapy for uncomplicated P. falciparum
and P. vivaxmalaria (7, 17, 19). SP is also still widely used in Africa
for the intermittent preventive treatment (IPT) of malaria in in-
fants (6), children (3), and pregnant women (8). SP resistance has
been well characterized at the molecular level. Mutations involv-
ing residues 51, 59, 108, and 164 of P. falciparum dihydrofolate
reductase conferred cross-resistance to the antifolates pyrimeth-
amine and cycloguanil, whereas a mutation in residue 16 specifi-
cally conferred resistance to cycloguanil (16). The accumulation
of mutations in the enzyme dihydropteroate synthase (in which
Gly437 proved to be a key residue) was associated with sulfadox-
ine resistance in P. falciparum (18). Mutations involving other
residues in dihydrofolate reductase and dihydropteroate synthase
have also been linked to SP resistance in P. vivax isolates (1, 9).
More recently, other mechanisms of resistance to SP have been
proposed. Dahlström et al. (4) have suggested that mutations
(specifically, I876V andK1466R) inmultidrug resistance protein 1
may mediate an alternative mechanism of SP resistance in P. fal-
ciparum, and Martinelli et al. (10) have identified a mutation
(K392Q) in themdr2 gene in a P. chabaudi clone that was geneti-
cally linked to sulfadoxine resistance.
pfmdr2 is an ABC transporter gene that encodes a P-glycopro-
tein similar to that encoded by pfmdr1 (13). Although Ekong et al.
(5) reported increased transcription of pfmdr2 in chloroquine-
resistant parasites, other studies have demonstrated neither am-
plification nor overexpression of pfmdr2 (15, 21). To date, there
appears to be no evidence to suggest that pfmdr2 is involved in
drug resistance in P. falciparum.
In this paper, we assessed the association between single nucle-
otide polymorphisms in the sequence of pfmdr2 and in vitro resis-
tance to pyrimethamine (Pyr) in P. falciparum isolates.
Between 2004 and 2010, 140 P. falciparum isolates (55 from
Comoros, 18 from Cameroon, 18 from Republic of Ivory Coast,
11 from Senegal, 7 fromBurkina Faso, 2 fromMadagascar, 1 from
French Guyana, 1 from Mayotte, and 27 from 13 other African
countries) were collected from patients with uncomplicated ma-
laria who were hospitalized in different French hospitals, and the
isolates were sent to the French National Reference Center for
Malaria. In vitro susceptibility to Pyr was evaluated as described in
reference 11, and a threshold of 2,000 nM was applied to deter-
mine the in vitro resistance of P. falciparum isolates as defined by
Basco et al. (2). A 562-bp coding region of pfdhfrwas amplified by
PCR and sequenced as described in reference 12; three mutations,
including a Ser¡Asn change at codon 108, an Asn¡Ile change at
codon 51 and a Cys¡Arg change at codon 59, were analyzed.
Copy numbers and single nucleotide polymorphisms in the
pfmdr2 gene were evaluated as described in reference 20. All sta-
tistical analyses were performed using the R software package,
version 2.10.1.
The mean 50% inhibitory concentration (IC50) of Pyr for the
140 isolates was 3,093 nM (95% confidence interval [CI], 2,527 to
3,660; minimum and maximum, 9.43 and 19,654 nM). Of these
isolates, 69 had a Pyr IC50  2,000 nM (mean Pyr IC50  5,687
nM; 95% CI, 4,941 to 6,432) and were considered resistant; 71
isolates had a Pyr IC50 2,000 nM (mean Pyr IC50 573.3 nM;
95% CI, 425.2 to 721.4) and were considered susceptible to Pyr.
Regarding the pfdhfr gene polymorphism, 74% (104/140) of the
isolates had a point mutation at codon 51 (N51I); 73% (102/140)
had a mutation at codon 59 (C59R), and 79% (110/140) had a
mutation at codon 108 (S108N). Further, 69% (97/140) of the
isolates had a triple mutation in pfdhfr. All 140 isolates possessed
only one copy of the pfmdr2 gene. The analysis of the sequence of
pfmdr2 gene revealed three points of mutation: S208N, F423Y,
and K924E. There was no significant association between the
S208N or K924E mutation and in vitro resistance to Pyr (P  1;
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Fisher’s exact test). The difference between the median of the Pyr
IC50 (2,598 nM) for isolates harboring the Y substitution at codon
423 (n  81) and the median of the Pyr IC50 (890 nM) for wild-
type isolates (n 59)was statistically significant (P 0.02;Mann-
Whitney test).
There was no statistically significant correlation between the
F423Y mutation in pfmdr2 and the mutation in pfdhfr (P 0.14;
Fisher’s exact test). As illustrated in Fig. 1, 16 isolates were wild
type for both the pfmdr2 and pfdhfr genes; the mean Pyr IC50 for
these isolates was 434.6 nM (95% CI, 0 to 1,014; minimum and
maximum, 10 and 4,214 nM). A total of 13 isolates had the F423Y
mutation in pfmdr2 and were wild type for pfdhfr; the mean Pyr
IC50 for these isolates was 170.1 nM (95% CI, 0 to 459.3; mini-
mum andmaximum, 10 and 1,762 nM). A total of 43 isolates were
wild type for pfmdr2 and mutant type for pfdhfr (with at least one
of the mutations N51I, C59R, and S108N); the mean Pyr IC50 for
these isolates was 3,229 nM (95% CI, 2,186 to 4,272; minimum
and maximum, 9.43 and 13,294 nM). A total of 68 isolates were
mutant type for both the pfmdr2 and pfdhfr genes; the mean Pyr
IC50 for these isolates was 4,192 nM (95% CI, 3,362 to 5,022;
minimum and maximum, 50 and 19,654 nM). There was no sta-
tistically significant association between the median of the Pyr
IC50 (50 nM) for isolateswith both pfmdr2 and the pfdhfrwild type
and the median of the Pyr IC50 (50 nM) for isolates with the
mutant type for pfmdr2 and the wild type for pfdhfr (P  0.25;
Mann-Whitney test). The difference between the median of the
Pyr IC50 (1,993 nM) of pfmdr2 wild-type and pfdhfrmutant-type
isolates and the median of the Pyr IC50 (3,255 nM) for isolates
harboring the Y substitution at codon 423 and a pfdhfr mutation
was statistically significant (P 0.0438; Mann-Whitney test).
The in vitro resistance to Pyr (Pyr IC50 2,000 nM) was ana-
lyzed using a logistic regression model (Table 1). The mutation
F423Y in pfmdr2 (OR 2.12 [95% CI, 1.02 to 4.59]; P 0.0489)
and the mutation N51I, C59R, or S108N in pfdhfr (OR  42.34
[95%CI, 5.52 to 324.61]; P 0.0003) (Hosmer-Lemeshow good-
ness-of-fit test; P  0.77) were independently associated with in
vitro resistance to Pyr.
MDR2 is associated with heavy metal ion efflux and resistance
to cadmium (14). MDR2 may be involved in the transport of
organic anions, such as folate or pABA, as has been suggested for
FIG 1 Pyrimethamine IC50s (in nanomoles) of the 140 Plasmodium falciparum isolates according to their genotypes.







(95% CI)a P valueb
Adjusted OR
(95% CI) P valuec
pfmdr2
F423 37 (26.4) 22 (15.7) 1 (reference) 1 (reference)
Y423 34 (24.3) 47 (33.6) 2.31 (1.11–4.91) 0.017 2.12 (1.02–4.59) 0.0489
pfdhfr
Wild type 28 (20) 1 (0.7) 1 (reference) 1 (reference)
Mutant type 43 (30.7) 68 (48.6) 43.36 (6.67–1,819.1) 0.0001 42.34 (5.52–324.61) 0.0003
a OR, odds ratio; CI, 95% confidence interval.
b Fisher’s exact test.
c Multivariate logistic regression model.
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MRP1 (4); it may be also implicated in the transport of sulfadox-
ine, as suggested byMartinelli et al. (10). Interestingly, in the latter
study, an association between the in vivo resistance of Plasmodium
chabaudi to sulfadoxine and amutation in themdr2 gene has been
shown. The same investigation performed with Plasmodium fal-
ciparum would be really interesting, but no laboratory is able to
evaluate the sulfadoxine IC50 with sufficient reproducibility. As
MDR2 (like MDR1, which is well known to be an efflux pump
involved in Plasmodium falciparum resistance to mefloquine) be-
longs to the ABC transporter family, the F423Y mutation in
MDR2might be associatedwith the efflux of pyrimethamine from
outside the parasite. This AAmodification concerns a cytoplasmic
loop of the MDR2 protein and does not represent a significant
alteration in terms of size and charge characteristics of the side
chain, as phenylalanine and tyrosine are both hydrophobic. But
this tyrosine could be a phosphorylation site, and it is known that
protein structure and activity can be modulated by phosphoryla-
tion of tyrosine residues. The mechanisms of P. falciparum resis-
tance to SP are probably multigenic; it is important for all of these
underlying mechanisms to be elucidated, because SP is still used
for the IPT ofmalaria inAfrica. The results of the present study are
of interest from this point of view. But further investigations
would be necessary to confirm these data with field isolates in
particular and also to evaluate the potential association between
this pfmdr2mutation and the resistance of P. falciparum to sulfa-
doxine.
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